# Hematologic Malignancies Program

> **NIH NIH P30** · MAYO CLINIC ROCHESTER · 2021 · $99,154

## Abstract

HEMATOLOGIC MALIGNANCIES PROGRAM PROJECT SUMMARY
The Hematologic Malignancies Program (HMP) is composed of 51 scientists, and clinical investigators from 7
departments at Mayo Clinic in Rochester, MN (MCR), Arizona (MCA), and Florida (MCF). The Program is co-
led by Drs. Ansell (MCR), Bergsagel (MCA) and Chanan-Khan (MCF). The HMP aims are to 1) investigate the
epidemiology of hematologic malignancies and mechanisms of progression, 2) characterize the molecular and
cell biology of hematologic malignancies to identify new therapeutic targets, and 3) develop and test new
therapies. To accomplish these aims, the HMP is organized into 4 disease groups (DGs) that are composed of
basic and translational research scientists, hematopathologists, and clinicians. The DGs meet weekly or
biweekly to discuss research results, clinical trial activities, and requests for use of biobank samples and
ensure that research is meeting the needs of the patients in our catchment area. Annual peer-reviewed direct
funding to HMP members is $4.6M, with 93% from the National Cancer Institute. This includes 2 SPOREs
(Lymphoma and Multiple Myeloma), 15 R01s, 2 R41s, 1 R21, 1 U54, 5 Multiple Myeloma Research Foundation
and 2 Leukemia and Lymphoma Society grants. Since 2012, the HMP has recruited 10 new scientists who
focus on key research areas ranging from cell signaling to cancer survivorship. Major scientific contributions by
the HMP since 2012 include a major role in the approval of nivolumab in Hodgkin lymphoma, leadership in
genome wide association studies (GWAS) identifying susceptibility loci in large cell lymphoma, leadership in
trials establishing the role of ibrutinb in CLL, and leadership in trials including bortezomib in frontline therapy for
multiple myeloma. The HMP continues to have a robust clinical trials program that enrolls over 500 patients
each year to therapeutic clinical trials. Members have contributed 1172 publications to the literature since
2013, 43% of which are intraprogrammatic and 30% interprogrammatic. HMP members have extensive
collaborations with members in the Gene and Virus Therapy, Experimental Therapeutics, and Genetic
Epidemiology and Risk Assessment Programs. HMP members make extensive use of numerous Shared
Resources, with substantial use of Biospecimens Accessioning & Processing, Biostatistics, and Pharmacy.
Significant institutional and philanthropic (Predolin Foundation) support continues for HMP-related research. In
the next funding period, we will mentor young investigators and focus on developing tools to integrate genomic
information into the individual care plans for our patients.

## Key facts

- **NIH application ID:** 10113611
- **Project number:** 5P30CA015083-47
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** STEPHEN M ANSELL
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $99,154
- **Award type:** 5
- **Project period:** 1997-04-25 → 2024-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10113611

## Citation

> US National Institutes of Health, RePORTER application 10113611, Hematologic Malignancies Program (5P30CA015083-47). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10113611. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*